Clinical trial
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic…
NCT00022971 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00022971 |
|---|---|
| Title | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia |
| Official title | Combination Antibody Therapy With Apolizumab (1D10) and Rituximab (CD20) in Relapsed Lymphoma and CLL |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma |
| Intervention type | Biological |
| Interventions | Apolizumab, Rituximab |
| Enrollment | 35 |
| Start date | Aug 15, 2001 |
| Primary completion | Jan 22, 2010 |
| Completion | Mar 17, 2017 |
| First posted | Aug 20, 2001 |
| Last update posted | Dec 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: